Opendata, web and dolomites

BGV1 SIGNED

New vaccine for a paradigm shift in Brucellosis, one of the world’s most widespread zoonotic diseases affecting humans

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BGV1 project word cloud

Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.

benefits    serious    bioterrorism    prevalent    tests    pregnant    suffer    small    diagnostics    caused    successful    globalisation    severely    veterinary    first    losses    zoonotic    environmental    bgv1    mass    candidate    minimal    eradication    ruminants    unnecessary    livestock    vaccines    species    vaccine    exhibiting    generate    medicine    outbreaks    endemic    greenvac    latin    integration    diagnostic    2028    anyone    brucellosis    melitensis    amidst    keepers    residual    classic    interference    serodiagnostic    lactating    poor    disease    human    eliminate    shift    antibiotics    evading    rate    health    standard    brucella    incidence    mediterranean    resistance    america    protective    animal    radical    animals    profile    infection    overcomes    virulent    paradigm    safety    lower    threats    81bn    cumulative    impacts    lives    replace    regions    safe    drawbacks    world    livelihoods    economic    anywhere    enhanced    designed    1950s    antibiotic    asia    rising    transmissibility    avirulent    virulence    relatively    africa    global    vaccination    science    humans    treatable    efficacy    combined    mainly    limited    time   

Project "BGV1" data sheet

The following table provides information about the project.

Coordinator
BRUCELLA GREEN VAC SL 

Organization address
address: PLAZA LAMITURRI, 10, 1 A
city: MUTILVA
postcode: 31192
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙005˙250 €
 EC max contribution 1˙403˙675 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-SMEInst-2018-2020-3
 Funding Scheme SME-2b
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRUCELLA GREEN VAC SL ES (MUTILVA) coordinator 1˙403˙675.00

Map

 Project objective

Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucellosis is endemic in most of Asia, Africa and Latin America and is prevalent in the EU Mediterranean regions. Currently vaccines for Brucellosis, around since the 1950s, suffer from serious safety drawbacks mainly due to residual virulence for animals and humans. Combined with rising antibiotic resistance, their use is relatively limited.

GreenVac is developing BGV1, the first vaccine in over 60 years against Brucella melitensis in small ruminants that overcomes the main drawbacks of existing vaccines. BGV1 has been designed to a) be avirulent for animals, b) eliminate interference with diagnostic tests after vaccination, c) have low potential transmissibility to humans and, d) be treatable with standard antibiotics. BGV1 is a strong candidate to replace the classic virulent vaccine, exhibiting a safe profile with an enhanced protective efficacy, no residual virulence and minimal serodiagnostic interference.

A successful BGV1 EU-project will allow, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. The reduction of B. melitensis outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2028 by evading unnecessary diagnostics costs and losses caused by the infection. It will lead to a lower disease incidence in humans amidst ever rising globalisation and bioterrorism threats to anyone, anywhere. BGV1 will contribute to the objectives of the One Health Initiative: One World, One Health, One Medicine to improve the lives of all species through the integration of human medicine, veterinary medicine and environmental science.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More